Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia DermAI®* is an AI application designed to help pathologists improve speed and confidence in the diagnosis of skin disease, automatically providing a digital read on each case and categorizing the case based on its diagnostic attributes. DermAI has been developed to address your lab’s key challenges: growing case volume, diagnostic complexity, and increasing demands on pathologists.

READ MORE: Unilabs projects DermAI may decrease turnaround time for melanoma cases by 30-40% Link Arrow

*For Research Use Only in the United States: requires FDA clearance.

New Research Spotlight:

An AI Breakthrough in Dermatopathology

Proscia’s work in AI-enabled computational pathology recently demonstrated a breakthrough in its detection of melanoma, the deadliest form of of skin cancer. In recent studies conducted with University of Florida, Thomas Jefferson University Hospital, and Cedars-Sinai, we demonstrated:

  • a sensitivity of 93% and a specificity of 91% in the detection of invasive melanoma and melanoma in situ
  • the classification of basal cell carcinoma and squamous cell carcinoma—which account for a combined 97% of all skin cancers—with an AUC of .97 and .95, respectively
  • an ability to categorize 93% of melanomas into a “suspicious” group comprising only 9% of total case volume
  • real-world performance of AI in a live deployment of 1,422 skin biopsies

These findings, along with Proscia’s additional research, demonstrate the potential of AI to deliver faster diagnoses, improve patient outcomes, and increase laboratory productivity.

View Infographic: The Future of Skin Cancer Diagnosis

Research Paper

A Pathology Deep Learning System Capable of Triage of Melanoma Specimens Utilizing Dermatopathologist Consensus as Ground Truth

Download Now


Using Artificial Intelligence with Dermatopathologist Consensus to Prioritize Melanoma

Learn more



Hear from Proscia experts about the tremendous promise of AI in pathology with Cancer Wellness

Read now


Julianna Ianni, VP of AI R&D, discusses AI research, DermAI and deep learning with Unite.AI

Read now


AI Melanoma Detection: Promise and Real-World Impact

Dermatopathologists Dr. Kiran Motaparthi (University of Florida) and Dr. Jason Lee (Thomas Jefferson University Hospital) discuss their prospective study work with Proscia AI, its current quality and efficiency impacts, and its potential to assist in the diagnosis of skin diseases such as melanoma.

Tuesday, November 09, 2021 | 01:00 PM ET


View On Demand

Proscia DermAI* automatically classifies every dermatopathology slide, leveraging a highly accurate algorithm—based on more than 13,000 images—to streamline your high-volume dermatopathology workflow.

DermAI highlights the promise of AI to deliver value in routine practice by:

  • Helping pathologists prioritize their worklists
  • Ensuring that cases are most efficiently routed to the right pathologist
  • Providing a second read on every case for extra confidence

In this video, Dr. Thomas G. Olsen, MD and Dr. Clay J. Cockerell, MD MBA, talk about the potential impact of AI for dermatopathology

Watch Now


*For Research Use Only in the United States: requires FDA clearance.


Partners in Dermopathology Breakthroughs

Proscia is working with leading laboratories to accelerate the validation of these and other AI solutions.

If you’re interested in learning more, contact us.

Our website uses cookies. By using this site, you agree to its use of cookies.